BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals appoints Steve Frank to its Board of Directors, bolstering leadership as the company continues to develop novel treatments for rare diseases, including its oral complement factor B inhibitor FABHALTA.

BioCryst Pharmaceuticals Inc. is navigating a complex biotech landscape, with its upcoming earnings report and investor conferences set to shape its market trajectory, driven by its innovative pipeline and potential for its complement inhibitor FABHALTA.